University of Groningen
Pro- and anti-fibrotic agents in liver fibrosis Suriguga, S.
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Suriguga, S. (2019). Pro- and anti-fibrotic agents in liver fibrosis: Perspective from an ex vivo model of liver fibrosis.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Pro- and anti-fibrotic agents
in liver fibrosis
Perspective from an ex vivo model of liver fibrosis
Suriguga
Paranymphs
Emilia Gore Gerian Prins
The research presented in this PhD thesis was performed at the Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, the Netherlands
Cover and layout: Suriguga
Printed: ProefschriftMaken||www.proefschriftmaken.nl ISBN (printed version): 978-94-034-1551-2
ISBN (electronic version): 978-94-034-1550-5 © Suriguga, 2019
All right reserved. Copyright of the published articles is with the corresponding journal or otherwise with the author. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing from author or the copyright-owning journal.
Pro- and anti-fibrotic agents
in liver fibrosis
Perspective from an ex vivo model of liver fibrosis
PhD thesis
to obtain the degree of PhD at the University of Groningen
on the authority of the
Rector Magnificus Prof. E. Sterken and in accordance with
the decision by the College of Deans. This thesis will be defended in public on
Monday 8 April 2019 at 09:00 hours
by
Suriguga
born on 22 November 1987 in Nei Mongol, China
Supervisors
Prof. P. Olinga
Prof. G.M.M. Groothuis
Assessment Committee
Prof. R.A. Bank
Prof. H.G.D. Leuvenink Prof. R. Safadi
Contents
Chapter 1 Introduction, scope and aims ... 7
Chapter 2 Host microbiota dictates the pro-inflammatory impact of LPS in the murine liver ... 13
Chapter 3 LPS aggravates fibrosis in early-onset but not end- stage human liver fibrosis ... 31
Chapter 4 Evaluating the anti-fibrotic potency of galunisertib in a human ex vivo model of liver fibrosis ... 67
Chapter 5 In vitro and ex vivo anti-fibrotic effects of LY2109761, a small molecule inhibitor against TGF-β ... 93
Chapter 6 Targeting oxidative stress for the treatment of liver fibrosis... 125
Chapter 7 General discussion and perspectives ... 155
Chapter 8 Summary ... 169
Chapter 9 Abbreviations ... 177
Author affiliation ... 179
Acknowledgements ... 181
